The Expanding Market Potential of Mental Health
We’re on the cusp of seeing huge changes in mental health.
At Holmusk, we are leveraging real-world data through our NeuroBlu platform and NeuroBlu Health (also called MaST in UK), a tool developed in collaboration with the NHS, to drive precision psychiatry, optimize patient outcomes, and improve resource allocation across healthcare systems.
Here’s how we’re moving mental health to the forefront of a healthcare revolution.
A Profound Transformation
The mental health sector is on the brink of a profound transformation.
The need is there. Mental health conditions are escalating: inequalities in treating conditions will cost the U.S. $14 trillion by 2040. That’s according to analysis from the Deloitte Center for Health Solutions.
The ripple effects of untreated or poorly treated mental health conditions ripple out into chronic health issues as well as workforce productivity losses. We’re at a crossroads where disruptive change can align clinical advancements with real-world applications.
At the heart of this transformation lies data-driven mental health.
My goal in building Holmusk’s NeuroBlu platform has been to create a system that mirrors the functionality and indispensability of a Bloomberg Terminal for mental health research and care.
NeuroBlu is designed to provide real-world data that enables precise, personalized treatment plans and allows clinicians to identify the right intervention for each individual. This type of approach can revolutionize care by allowing insight into the nuanced profiles of each patient. In turn, this will optimize outcomes and reduce the trial-and-error cycle so prevalent in psychiatry.
We’re already seeing successes. Together with the NHS in the United Kingdom, NeuroBlu Health has been helping clinical teams and front line workers improve decision-making capabilities for care protocol, resource allocation and patient flow.
NeuroBlu Health has been:
Implemented in 12 mental health trusts so far in England
Is saving each of the NHS trusts approx. £1.7 million over 6 month period
Is reducing the overall duration of patient mental health crises
And is reducing the length of inpatient stay
This kind of innovation can bring about significant improvements to several types of public and private payor systems. The current model, where around 5% of a healthcare network’s population accounts for 20% of mental health spending, is unsustainable.
Or think about large scale public health systems like the VA, where more than half of veterans need mental health treatment, and in 2021, approximately 17.5 veterans died by suicide every day.
With real-world data platforms like Holmusk’s NeuroBlu, we are witnessing the early stages of a new era. Mental health is no longer an isolated healthcare niche; it is a growth sector on the cusp of transformation.
Bringing Holmusk to a Global Audience
Today, I spoke at the European Parliament in Brussels for Brain Innovation Days, diving into “Moving the Needle on Mental Health Outcomes.” This came after well-received talks at the Johnson & Johnson JLABS CEO summit and the Kennedy Forum Alignment for Progress Conference.
In Brussels, I shared insights on how Holmusk can redefine mental healthcare outcomes and helped uncover solutions that have long been a dream.
It was a call to address the urgency for change—one that demands both tenacity and vision.